ContraFect (ContraFect) Institutional Ownership : 0.02% (As of May. 01, 2024)

View and export this data going back to 2014. Start your Free Trial

What is ContraFect Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ContraFect's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ContraFect's Insider Ownership is 13.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ContraFect's Float Percentage Of Total Shares Outstanding is 89.42%.

ContraFect Institutional Ownership Historical Data

The historical data trend for ContraFect's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect Institutional Ownership Chart

ContraFect Historical Data

The historical data trend for ContraFect can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.09	0.09	0.18	0.27	0.27	0.05	0.02	0.02	0.02	0.02

ContraFect Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

ContraFect (ContraFect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701

Website

https://www.contrafect.com

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

Executives

Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger	officer: VP Finance	238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff	director	1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low	director	EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi	director	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner	officer: SVP Business Development	30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	10 percent owner	BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd	10 percent owner	FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino	officer: Chief Medical Officer	757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos	officer: General Counsel	207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto	director	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421